logo-loader
Redx Pharma Plc

Redx Pharma shares soar 69% as executive chairman increases stake

The drug developer said following this acquisition, Iain Ross will hold 600,000 ordinary shares in the company, representing 0.47% of the issued share capital

Redx Pharma
In lunchtime trading company’s shares soared 69.2% to 16.5p

Redx Pharma Plc (LON:REDX) shares soared as the company announced that Iain Ross, its executive chairman, has today acquired 150,000 Redx oridinary shares at a price of 11p per share.

The drug developer said following this acquisition, Iain Ross will hold 600,000 ordinary shares in the company, representing 0.47% of the issued share capital.

Yesterday Redx Pharma's shares jumped 48% as the company announced the appointment of AstraZeneca PLC (LON:AZN) Lisa Anson as its new chief executive.

READ: Redx Pharma shares soar 48% after it recruits heavy hitter from drugs major AstraZeneca

In lunchtime trading company’s shares soared 69.2% to 16.5p.

 

Quick facts: Redx Pharma Plc

Price: £0.08

Market: AIM
Market Cap: £10.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

New Redx CEO bringing leadership and skills to 'capitalise on its great science'

Lisa Anson, the new chief executive at Redx Pharma Plc (LON:REDX), sat down with Proactive's Andrew Scott just weeks after taking on the new role. Anson was the president of AstraZeneca PLC’s (LON:AZN) UK division immediately prior to joining, while she's also held various other senior...

on 19/7/18

2 min read